Expert Video - What are the challenges to mutation-driven MDS treatment?

Rafael Bejar, MD, PhD, head of the MDS Center of Excellence at the University of California, San Diego, explains how the small number of mutation-driven MDS treatments remains a challenge. These treatments include targeted therapy for mutations in the genes IDH1 and IDH2, as well as luspatercept for people with a mutation in SF3B1. Learning about resistance mutations is also important for improving treatment response and developing additional mutation-driven MDS therapies.

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.

Other Modules:

Management and Treatment of MDS

Managing and Treating MDS-related Anemia

Understanding Myelodysplastic Syndromes

Understanding MDS-related Anemia

Understanding Erythropoiesis

Diagnosis of MDS

Understanding Genetic Mutations in MDS

Blood and Marrow Transplantation in MDS

Understanding Clinical Trials in MDS

Including Everyone in Clinical Trials for MDS

Animation - Mutation-Driven Therapy in MDS

Slide Show - Mutation-Driven Therapy in MDS

Expert Videos

1. How does my genetic mutation profile impact the treatment of my MDS?

2. What are mutation-driven MDS treatments?

3. What are the goals of mutation-driven MDS treatments?

4. How does my MDS genetic mutation permit personalized treatment decisions?

5. What questions should I ask my doctor about mutation-driven MDS treatments?

6. What are the challenges to mutation-driven MDS treatment?

7. When should genetic testing for MDS be done?

8. How do MDS genetic mutations influence decisions for stem cell transplant?

Patient Videos

9. Becky's story: How has your gene mutation profile affected your MDS treatment experience?

10. Donna's story: How has your gene mutation profile affected your MDS treatment experience?

11. Holly's story: How has your gene mutation profile affected your MDS treatment experience?

12. Becky's story: What has been the greatest success with your MDS treatment?

13. Donna's story: What has been the greatest success with your MDS treatment?

14. Holly's story: What has been the greatest success with your MDS treatment?

15. Becky's story: What has been the greatest challenge with your MDS treatment?

16. Donna's story: What has been the greatest challenge with your MDS treatment?

17. Holly's story: What has been the greatest challenge with your MDS treatment?

This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.

This activity is supported by an educational grant from Acceleron Pharma, Bristol-Myers Squibb, Celgene Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals, and Takeda Oncology.

This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.